These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26824047)

  • 41. ADP receptor antagonism: what's in the pipeline?
    Angiolillo DJ
    Am J Cardiovasc Drugs; 2007; 7(6):423-32. PubMed ID: 18076209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.
    Trenk D; Kristensen SD; Hochholzer W; Neumann FJ
    Thromb Haemost; 2013 May; 109(5):834-45. PubMed ID: 23238773
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in the monitoring of anti-P2Y12 therapy.
    Harrison P
    Platelets; 2012; 23(7):510-25. PubMed ID: 22916724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
    Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?
    Samoš M; Fedor M; Kovář F; Duraj L; Stančiaková L; Galajda P; Staško J; Kubisz P; Mokáň M
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):117-20. PubMed ID: 26340464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. P2Y12 platelet inhibition in clinical practice.
    Damman P; Woudstra P; Kuijt WJ; de Winter RJ; James SK
    J Thromb Thrombolysis; 2012 Feb; 33(2):143-53. PubMed ID: 22183178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
    El Ghannudi S; Ohlmann P; Jesel L; Radulescu B; El Adraa E; Crimizade U; Wiesel ML; Gachet C; Morel O
    Atherosclerosis; 2011 Aug; 217(2):465-72. PubMed ID: 21524751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?
    Cattaneo M
    J Thromb Haemost; 2012 Mar; 10(3):327-36. PubMed ID: 22221409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
    Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
    Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
    Mshelbwala FS; Hugenberg DW; Kreutz RP
    J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversal of the platelet inhibitory effect of the P2Y
    Schoener L; Jellinghaus S; Richter B; Pfluecke C; Ende G; Christoph M; Quick S; Loehn T; Speiser U; Poitz DM; Mierke J; Strasser RH; Ibrahim K
    Clin Res Cardiol; 2017 Nov; 106(11):868-874. PubMed ID: 28653184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.